Navigation Links
ResearchDx and Menarini Silicon Biosystems Launch DEPArray HER2 for Breast and GEA Cancers
Date:10/5/2017

ResearchDx, the leading biopharma companion diagnostics provider and Menarini Silicon Biosystems, worldwide manufacturer of image-based cell sorting products and services, jointly announce the launch of DEPArray HER2. The fluorescence in situ hybridization (FISH)-based assay has been validated as a clinical research laboratory developed test (LDT) and is performed by PacificDx, a CAP/CLIA certified and wholly owned subsidiary laboratory of ResearchDx.

Close to 300,000 breast and gastroesophageal adenocarcinoma (GEA) tumors are diagnosed each year in the United States. An estimated 20% of those tumors harbor HER2 gene amplifications. Accurate assessment of HER2 status in breast and GEA cancers is critical for identifying patients predicted to respond to anti-HER2 targeted therapies. Traditional tissue-based assessment of HER2 gene status can be problematic due the mixture of tumor and stromal (normal) tissue in a standard biopsy sample. Compounding the problem of tissue heterogeneity is the known intra-tumor genetic heterogeneity of many breast and GEA cancers such that only a small percentage of the tumor contains HER2 gene amplification.

The DEPArray HER2 test leverages cell isolation capabilities of DEPArray™ NxT technology allowing isolation of pure tumor cell populations from heterogeneous tumor/normal tissue samples. The HER2 test is performed on pure tumor populations isolated from stained cell suspensions digitally sorted using the DEPArray NxT, thus eliminating tissue heterogeneity and allowing true genetic heterogeneity to be revealed more accurately.

“We are the first clinical laboratory to offer HER2 gene testing on pure cell populations isolated from tumor tissue by DEPArray NxT technology,” said Shelly Gunn MD, PhD. ResearchDx’s Chief Medical Officer and Medical Director of the PacificDx clinical laboratory. “We are looking forward to validating additional applications for DEPArray NxT technology including isolation of circulating tumor cells (CTCs) for liquid biopsy applications in a variety of solid tumors.”

“We are excited to see the launch our first DEPArray NxT-based clinical test in the U.S. Notably, this will provide physicians, and most importantly their patients, access to a solution in overcoming unresolved/equivocal HER2 status observed with tissue biopsies“ said Farideh Bischoff, PhD. Menarini Silicon Biosystems, Inc. Chief Clinical Development Officer.

The DEPArray HER2 test has a 5-7 day turn around time and can be performed in our CAP/CLIA certified laboratory on any archival tumor tissue sample. For more information about the test, please visit: http://www.pacificdx.com.

Read the full story at http://www.prweb.com/releases/2017/10/prweb14765621.htm.


'/>"/>
Source: PRWeb
Copyright©2017 Vocus, Inc.
All rights reserved


Related biology technology :

1. ResearchDx Appointment of New Chief Medical Officer to Meet NIH Push for Precision Medicine in Expediting Bench to Bedside" Strategies for Disease Treatment
2. ResearchDx and BioSmartSA Announce New Consulting Practice in Saudi Arabia
3. ResearchDx/PacificDx to Present High-Resolution HER2 Testing Data at the San Antonio Breast Cancer Symposium
4. Menarini and Meyer United In The Search For Rare Cells
5. Building quantum states with individual silicon atoms
6. Galectin Therapeutics: Turning Atlanta into Americas Next Silicon Valley
7. Next Silicon Valley BioTalks Tackles “Is EDC Becoming a Commodity?” at Onyx Pharmaceuticals HQ
8. MarketPublishers.com Added New Report on Silicon Tetrafluoride (CAS 7783-61-1) Market to Its Catalogue
9. NASA Scientists and Silicon Valley Space Center Partners Make Home Team Bid for Moffett Federal Airfield Development
10. MarketPublishers.com Added New Report on Silicon Nitride (CAS 12033-89-5) Market to Its Catalogue
11. Brainwave Signal Interpretation Software Company EyeMynd Announces Move to Silicon Valley
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/1/2018)... ... August 01, 2018 , ... ... results on the significant impact of a proprietary biofield energy treated supplement ... preclinical research assessed biomarkers for systemic and organ-specific inflammation, as well as, ...
(Date:7/31/2018)... N.Y. (PRWEB) , ... July 31, 2018 , ... ... of 2 additional CE/IVD marked molecular quality controls to its expanding CE/IVD product ... quality controls to our expanding CE/IVD QC offerings. ZeptoMetrix remains entirely committed to ...
(Date:7/27/2018)... ... July 27, 2018 , ... Representatives of ... Biotechnology Innovation Organization (BIO) met with U.S. Environmental Protection Agency (EPA) staff ... Substances Control Act (TSCA) Inventory Representation and Equivalency Determinations for Renewable and ...
(Date:7/25/2018)... ... July 25, 2018 , ... Eileen ... impact of a biofield energy treated nutraceutical to improve skin health parameters including ... for skin health and reported the following results:,     More ...
Breaking Biology Technology:
(Date:7/31/2018)... ... July 31, 2018 , ... ACEA Biosciences, is a privately owned ... has just introduced the xCELLigence RTCA S16, which the ideal entry level model for ... computer, the S16can be placed in any standard CO2 tissue culture incubator. The ...
(Date:7/31/2018)... ... July 31, 2018 , ... Lifecycle Biotechnologies, ... Business Development Manager. In this role, Mr. Muzek will lead the company-wide industrial ... growth and expansion. , With over 20 years in business development, Mr. ...
(Date:7/30/2018)... ... 2018 , ... TC Slade, an evidence-based healer, today released ... treated Vitamin D3 on the strength and health of bones. , The ... ALP, a bone-specific enzyme ,     Over 240% increase in collagen levels , ...
Breaking Biology News(10 mins):